Anavex gains after seeking EU marketing nod for Alzheimer’s drug

Anavex Life Sciences (NASDAQ:AVXL) traded ~10% higher in the premarket after the company said it submitted a marketing authorization application to seek EU approval for its Alzheimer’s candidate blarcamesine (ANAVEX2-73).

The orally delivered small molecule targeting SIGMAR1 and muscarinic receptors